Viviane Karoline da Silva Carvalho

Should rare and ultrarare diseases be treated differently in health coverage decisions?

Health technology assessment (HTA) is widely used to inform coverage and reimbursement decisions in health systems by integrating evidence on clinical effectiveness, safety, cost-effectiveness, and broader social considerations. However, the application of conventional HTA frameworks to rare diseases remains chal...